<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:08:23Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6580745" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6580745</identifier>
        <datestamp>2019-07-02</datestamp>
        <setSpec>bmjgroup</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Gut</journal-id>
              <journal-id journal-id-type="iso-abbrev">Gut</journal-id>
              <journal-id journal-id-type="hwp">gutjnl</journal-id>
              <journal-id journal-id-type="publisher-id">gut</journal-id>
              <journal-title-group>
                <journal-title>Gut</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0017-5749</issn>
              <issn pub-type="epub">1468-3288</issn>
              <publisher>
                <publisher-name>BMJ Publishing Group</publisher-name>
                <publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6580745</article-id>
              <article-id pub-id-type="pmcid">PMC6580745</article-id>
              <article-id pub-id-type="pmc-uid">6580745</article-id>
              <article-id pub-id-type="pmid">30108162</article-id>
              <article-id pub-id-type="pmid">30108162</article-id>
              <article-id pub-id-type="publisher-id">gutjnl-2018-316408</article-id>
              <article-id pub-id-type="doi">10.1136/gutjnl-2018-316408</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Hepatology</subject>
                </subj-group>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>1506</subject>
                  <subject>2312</subject>
                </subj-group>
                <series-title>Original article</series-title>
              </article-categories>
              <title-group>
                <article-title>Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial</article-title>
              </title-group>
              <contrib-group>
                <contrib id="author-59261752" contrib-type="author">
                  <name>
                    <surname>Pinyol</surname>
                    <given-names>Roser</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib id="author-63387467" contrib-type="author">
                  <name>
                    <surname>Montal</surname>
                    <given-names>Robert</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib id="author-61284457" contrib-type="author">
                  <name>
                    <surname>Bassaganyas</surname>
                    <given-names>Laia</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib id="author-42083459" contrib-type="author">
                  <name>
                    <surname>Sia</surname>
                    <given-names>Daniela</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff2">2</xref>
                </contrib>
                <contrib id="author-46466941" contrib-type="author">
                  <name>
                    <surname>Takayama</surname>
                    <given-names>Tadatoshi</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff3">3</xref>
                </contrib>
                <contrib id="author-61242704" contrib-type="author">
                  <name>
                    <surname>Chau</surname>
                    <given-names>Gar-Yang</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff4">4</xref>
                </contrib>
                <contrib id="author-22078843" contrib-type="author">
                  <name>
                    <surname>Mazzaferro</surname>
                    <given-names>Vincenzo</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff5">5</xref>
                </contrib>
                <contrib id="author-53170733" contrib-type="author">
                  <name>
                    <surname>Roayaie</surname>
                    <given-names>Sasan</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff6">6</xref>
                </contrib>
                <contrib id="author-25088908" contrib-type="author">
                  <name>
                    <surname>Lee</surname>
                    <given-names>Han Chu</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff7">7</xref>
                </contrib>
                <contrib id="author-23299572" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7279-9702</contrib-id>
                  <name>
                    <surname>Kokudo</surname>
                    <given-names>Norihiro</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff8">8</xref>
                </contrib>
                <contrib id="author-61242991" contrib-type="author">
                  <name>
                    <surname>Zhang</surname>
                    <given-names>Zhongyang</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff9">9</xref>
                </contrib>
                <contrib id="author-45594654" contrib-type="author">
                  <name>
                    <surname>Torrecilla</surname>
                    <given-names>Sara</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib id="author-61242924" contrib-type="author">
                  <name>
                    <surname>Moeini</surname>
                    <given-names>Agrin</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib id="author-61243080" contrib-type="author">
                  <name>
                    <surname>Rodriguez-Carunchio</surname>
                    <given-names>Leonardo</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib id="author-23672558" contrib-type="author">
                  <name>
                    <surname>Gane</surname>
                    <given-names>Edward</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff10">10</xref>
                </contrib>
                <contrib id="author-22494854" contrib-type="author">
                  <name>
                    <surname>Verslype</surname>
                    <given-names>Chris</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff11">11</xref>
                </contrib>
                <contrib id="author-61243157" contrib-type="author">
                  <name>
                    <surname>Croitoru</surname>
                    <given-names>Adina Emilia</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff12">12</xref>
                </contrib>
                <contrib id="author-34923905" contrib-type="author">
                  <name>
                    <surname>Cillo</surname>
                    <given-names>Umberto</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff13">13</xref>
                </contrib>
                <contrib id="author-26272401" contrib-type="author">
                  <name>
                    <surname>de la Mata</surname>
                    <given-names>Manuel</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff14">14</xref>
                </contrib>
                <contrib id="author-61243282" contrib-type="author">
                  <name>
                    <surname>Lupo</surname>
                    <given-names>Luigi</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff15">15</xref>
                </contrib>
                <contrib id="author-61243356" contrib-type="author">
                  <name>
                    <surname>Strasser</surname>
                    <given-names>Simone</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff16">16</xref>
                </contrib>
                <contrib id="author-39566902" contrib-type="author">
                  <name>
                    <surname>Park</surname>
                    <given-names>Joong-Won</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff17">17</xref>
                </contrib>
                <contrib id="author-61259623" contrib-type="author">
                  <name>
                    <surname>Camps</surname>
                    <given-names>Jordi</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff18">18</xref>
                </contrib>
                <contrib id="author-61259642" contrib-type="author">
                  <name>
                    <surname>Solé</surname>
                    <given-names>Manel</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib id="author-53170706" contrib-type="author">
                  <name>
                    <surname>Thung</surname>
                    <given-names>Swan N</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff2">2</xref>
                </contrib>
                <contrib id="author-42045683" contrib-type="author">
                  <name>
                    <surname>Villanueva</surname>
                    <given-names>Augusto</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff2">2</xref>
                </contrib>
                <contrib id="author-61259877" contrib-type="author">
                  <name>
                    <surname>Pena</surname>
                    <given-names>Carol</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff19">19</xref>
                </contrib>
                <contrib id="author-61259896" contrib-type="author">
                  <name>
                    <surname>Meinhardt</surname>
                    <given-names>Gerold</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff19">19</xref>
                </contrib>
                <contrib id="author-41561155" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9826-0753</contrib-id>
                  <name>
                    <surname>Bruix</surname>
                    <given-names>Jordi</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                </contrib>
                <contrib id="author-49378154" contrib-type="author">
                  <name>
                    <surname>Llovet</surname>
                    <given-names>Josep M</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff1">1</xref>
                  <xref ref-type="aff" rid="aff2">2</xref>
                  <xref ref-type="aff" rid="aff20">20</xref>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label><institution content-type="department">BCLC Group, Liver Unit</institution>, <institution>Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)–Hospital Clínic, CIBERehd, Universitat de Barcelona</institution>, <addr-line content-type="city">Barcelona</addr-line>, <country>Spain</country></aff>
              <aff id="aff2"><label>2</label><institution content-type="department">Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Department of Hematology/Oncology, Department of Medicine, Department of Pathology, Recanati Miller Transplantation Institute)</institution>, <institution>Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai</institution>, <addr-line content-type="city">New York City</addr-line>, <addr-line content-type="state">New York</addr-line>, <country>USA</country></aff>
              <aff id="aff3"><label>3</label><institution content-type="department">Department of Digestive Surgery</institution>, <institution>Nihon University School of Medicine</institution>, <addr-line content-type="city">Tokyo</addr-line>, <country>Japan</country></aff>
              <aff id="aff4"><label>4</label><institution content-type="department">Department of surgery</institution>, <institution>Taipei Veterans General Hospital</institution>, <addr-line content-type="city">Taipei</addr-line>, <country>Taiwan</country></aff>
              <aff id="aff5"><label>5</label><institution content-type="department">Hepatology and Liver Transplantation Unit, Department of Surgery</institution>, <institution>University of Milan and Fondazione IRCCS Istituto Nazionale dei Tumori</institution>, <addr-line content-type="city">Milan</addr-line>, <country>Italy</country></aff>
              <aff id="aff6"><label>6</label><institution content-type="department">Liver Cancer Program</institution>, <institution>White Plains Hospital, Montefiore Health</institution>, <addr-line content-type="city">New York City</addr-line>, <addr-line content-type="state">New York</addr-line>, <country>USA</country></aff>
              <aff id="aff7"><label>7</label><institution content-type="department">Department of Gastroenterology</institution>, <institution>Asan Medical Center, University of Ulsan College of Medicine</institution>, <addr-line content-type="city">Seoul</addr-line>, <country>South Korea</country></aff>
              <aff id="aff8"><label>8</label><institution content-type="department">Department of surgery</institution>, <institution>University of Tokyo</institution>, <addr-line content-type="city">Tokyo</addr-line>, <country>Japan</country></aff>
              <aff id="aff9"><label>9</label><institution content-type="department">Department of Genetics and Genomic Sciences</institution>, <institution>Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai</institution>, <addr-line content-type="city">New York City</addr-line>, <addr-line content-type="state">New York</addr-line>, <country>USA</country></aff>
              <aff id="aff10"><label>10</label><institution content-type="department">New Zealand Liver Transplant Unit</institution>, <institution>Auckland City Hospital</institution>, <addr-line content-type="city">Auckland</addr-line>, <country>New Zealand</country></aff>
              <aff id="aff11"><label>11</label><institution content-type="department">Department of Hepatology</institution>, <institution>University Hospital Leuven</institution>, <addr-line content-type="city">Leuven</addr-line>, <country>Belgium</country></aff>
              <aff id="aff12"><label>12</label><institution content-type="department">Departament of Medical Oncology</institution>, <institution>Fundeni Clinical Institute</institution>, <addr-line content-type="city">Bucharest</addr-line>, <country>Romania</country></aff>
              <aff id="aff13"><label>13</label><institution content-type="department">Unità Operativa di Chirurgia Epatobiliare e Trapianto Epatico</institution>, <institution>Azienda Ospedaliera Università di Padova</institution>, <addr-line content-type="city">Padova</addr-line>, <country>Italy</country></aff>
              <aff id="aff14"><label>14</label><institution content-type="department">Unit of Hepatology and Liver Transplantation</institution>, <institution>CIBERehd, IMIBIC, University Hospital Reina Sofia</institution>, <addr-line content-type="city">Cordoba</addr-line>, <country>Spain</country></aff>
              <aff id="aff15"><label>15</label><institution content-type="department">Sezione Chirurgia Generale e Trapianti di Fegato</institution>, <institution>Policlinico di Bari</institution>, <addr-line content-type="city">Bari</addr-line>, <country>Italy</country></aff>
              <aff id="aff16"><label>16</label><institution content-type="department">AW Morrow Gastroenterology and Liver Centre</institution>, <institution>Royal Prince Alfred Hospital–University of Sydney</institution>, <addr-line content-type="city">Sydney</addr-line>, <addr-line content-type="state">New South Wales</addr-line>, <country>Australia</country></aff>
              <aff id="aff17"><label>17</label><institution content-type="department">Department of Cancer Control and Population Health</institution>, <institution>National Cancer Center</institution>, <addr-line content-type="city">Goyang</addr-line>, <country>South Korea</country></aff>
              <aff id="aff18"><label>18</label><institution content-type="department">Gastrointestinal and Pancreatic Oncology Group</institution>, <institution>IDIBAPS–Hospital Clínic, CIBERehd</institution>, <addr-line content-type="city">Barcelona</addr-line>, <country>Spain</country></aff>
              <aff id="aff19"><label>19</label><institution>Bayer HealthCare Pharmaceuticals</institution>, <addr-line content-type="city">Whippany</addr-line>, <addr-line content-type="state">New Jersey</addr-line>, <country>USA</country></aff>
              <aff id="aff20"><label>20</label><institution>Institució Catalana de Recerca i Estudis Avançats (ICREA)</institution>, <addr-line content-type="city">Barcelona</addr-line>, <country>Spain</country></aff>
              <author-notes>
                <corresp><label>Correspondence to</label> Dr Josep M Llovet, Liver Cancer Translational Research Laboratory, Barcelona Clinic Liver Cancer Group (BCLC), IDIBAPS-Hospital Clinic, Barcelona, 08036 Catalonia, Spain; <email>jmllovet@clinic.cat</email></corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <month>6</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>2</day>
                <month>10</month>
                <year>2018</year>
              </pub-date>
              <volume>68</volume>
              <issue>6</issue>
              <fpage>1065</fpage>
              <lpage>1075</lpage>
              <history>
                <date date-type="received">
                  <day>05</day>
                  <month>4</month>
                  <year>2018</year>
                </date>
                <date date-type="rev-recd">
                  <day>16</day>
                  <month>7</month>
                  <year>2018</year>
                </date>
                <date date-type="accepted">
                  <day>16</day>
                  <month>7</month>
                  <year>2018</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</copyright-statement>
                <copyright-year>2019</copyright-year>
                <license license-type="open-access">
                  <license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:href="gutjnl-2018-316408.pdf"/>
              <abstract>
                <sec>
                  <title>Objective</title>
                  <p>Sorafenib is the standard systemic therapy for advanced hepatocellular carcinoma (HCC). Survival benefits of resection/local ablation for early HCC are compromised by 70% 5-year recurrence rates. The phase 3 STORM trial comparing sorafenib with placebo as adjuvant treatment did not achieve its primary endpoint of improving recurrence-free survival (RFS). The biomarker companion study BIOSTORM aims to define (A) predictors of recurrence prevention with sorafenib and (B) prognostic factors with B level of evidence.</p>
                </sec>
                <sec>
                  <title>Design</title>
                  <p>Tumour tissue from 188 patients randomised to receive sorafenib (83) or placebo (105) in the STORM trial was collected. Analyses included gene expression profiling, targeted exome sequencing (19 known oncodrivers), immunohistochemistry (pERK, pVEGFR2, Ki67), fluorescence in situ hybridisation (VEGFA) and immunome. A gene signature capturing improved RFS in sorafenib-treated patients was generated. All 70 RFS events were recurrences, thus time to recurrence equalled RFS. Predictive and prognostic value was assessed using Cox regression models and interaction test.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>BIOSTORM recapitulates clinicopathological characteristics of STORM. None of the biomarkers tested (related to angiogenesis and proliferation) or previously proposed gene signatures, or mutations predicted sorafenib benefit or recurrence. A newly generated 146-gene signature identifying 30% of patients captured benefit to sorafenib in terms of RFS (p of interaction=0.04). These <italic>sorafenib RFS responders</italic> were significantly enriched in CD4<sup>+</sup> T, B and cytolytic natural killer cells, and lacked activated adaptive immune components. Hepatocytic pERK (HR=2.41; p=0.012) and microvascular invasion (HR=2.09; p=0.017) were independent prognostic factors.</p>
                </sec>
                <sec>
                  <title>Conclusion</title>
                  <p>In BIOSTORM, only hepatocytic pERK and microvascular invasion predicted poor RFS. No mutation, gene amplification or previously proposed gene signatures predicted sorafenib benefit. A newly generated multigene signature associated with improved RFS on sorafenib warrants further validation.</p>
                </sec>
                <sec>
                  <title>Trial registration number</title>
                  <p><ext-link ext-link-type="uri" xlink:href="NCT00692770">NCT00692770</ext-link>.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>hepatocellular carcinoma</kwd>
                <kwd>molecular oncology</kwd>
                <kwd>clinical trials</kwd>
                <kwd>tumour markers</kwd>
                <kwd>cancer</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-1">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003030</institution-id>
                      <institution>Agència de Gestió d’Ajuts Universitaris i de Recerca</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-2">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002809</institution-id>
                      <institution>Generalitat de Catalunya</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-3">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id>
                      <institution>National Cancer Institute</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-4">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000391</institution-id>
                      <institution>Association for International Cancer Research</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-5">
                  <funding-source>
                    <institution-wrap>
                      <institution>Spanish Health Ministry - Plan estratégico Nacional contra la Hepatitis C</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-6">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000801</institution-id>
                      <institution>Bayer HealthCare</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-7">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005347</institution-id>
                      <institution>American Association for the Study of Liver Diseases</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-8">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002704</institution-id>
                      <institution>Fundación Científica Asociación Española Contra el Cáncer</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-9">
                  <funding-source>
                    <institution-wrap>
                      <institution>Tisch Cancer Institute</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-10">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010661</institution-id>
                      <institution>Horizon 2020 Framework Programme</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-11">
                  <funding-source>
                    <institution-wrap>
                      <institution>Spanish National Health Institute</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-12">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001384</institution-id>
                      <institution>Samuel Waxman Cancer Research Foundation</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-13">
                  <funding-source>
                    <institution-wrap>
                      <institution>Spanish Ministry of Economy and Competitiveness</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-14">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000005</institution-id>
                      <institution>U.S. Department of Defense</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-15">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004587</institution-id>
                      <institution>Instituto de Salud Carlos III</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group id="funding-16">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007072</institution-id>
                      <institution>Onyx Pharmaceuticals</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>special-feature</meta-name>
                  <meta-value>unlocked</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <boxed-text id="BX1" position="float" orientation="portrait">
              <caption>
                <title>Significance of this study</title>
              </caption>
              <sec>
                <title>What is already known on this subject?</title>
                <list list-type="bullet">
                  <list-item>
                    <p>There is no standard adjuvant treatment after resection/ablation for hepatocellular carcinoma and thus this is an unmet medical need. The phase 3 STORM study did not show benefits for sorafenib compared with placebo in terms of recurrence-free survival (RFS). In some solid tumours, however, cancer therapies based on predictive biomarkers assessed post hoc have entered clinical practice (eg, KRAS mutations status for cetuximab in colorectal cancer). We are herein reporting a level B evidence of a companion study of the phase 3 STORM trial exploring prognostic factors and predictors of response to sorafenib.</p>
                  </list-item>
                </list>
              </sec>
              <sec>
                <title>What are the new findings?</title>
                <list list-type="bullet">
                  <list-item>
                    <p>In terms of prediction of response to sorafenib, none of the previously reported gene signatures or biomarkers (amplification VEGFA, pERK) were predictive to sorafenib efficacy. We have generated a new gene signature that is independent of whatever clinical-pathological variable and is able to discriminate patients who respond to sorafenib in terms of RFS. In terms of prognosis, we identified pERK and microvascular invasion as prognostic biomarkers of poor RFS. However, none of the tested gene-signatures or mutations were predictive of recurrence.</p>
                  </list-item>
                </list>
              </sec>
            </boxed-text>
            <boxed-text id="BX2" position="float" orientation="portrait">
              <caption>
                <title>Significance of this study</title>
              </caption>
              <sec>
                <title>How might it impact on clinical practice in the foreseeable future?</title>
                <list list-type="bullet">
                  <list-item>
                    <p>The study confirms the lack of known biomarkers as predictors of response to sorafenib, and proposes a gene signature at level B evidence (Simon <italic>et al</italic>, 2009) that once validated might help at selecting patients able to benefit from sorafenib in the setting of adjuvancy.</p>
                  </list-item>
                </list>
              </sec>
            </boxed-text>
            <sec id="s1">
              <title>Background</title>
              <p>Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, with nearly 850 000 new cases/year worldwide.<xref rid="R1" ref-type="bibr">1</xref> At early stages of the disease, surgical resection, liver transplantation and local ablation are considered the main treatments.<xref rid="R2" ref-type="bibr">2</xref> However, up to 70% of patients treated with resection or local ablation present tumour recurrence at 5 years.<xref rid="R1" ref-type="bibr">1</xref> Therefore, prevention of HCC recurrence—through the clearance of micrometastasis or de novo tumours by adjuvant treatments—is a major unmet medical need. In the past decade, a significant improvement in the management of advanced HCC has occurred. Sorafenib was first approved a decade ago<xref rid="R3" ref-type="bibr">3</xref>, and more recently other therapies have shown clinical benefits and/or US Food and Drug Administration approval as first (lenvatinib)<xref rid="R4" ref-type="bibr">4</xref> or second-line treatments (regorafenib<xref rid="R5" ref-type="bibr">5</xref>, cabozantinib<xref rid="R6" ref-type="bibr">6</xref>, nivolumab<xref rid="R7" ref-type="bibr">7</xref> and ramucirumab<xref rid="R8" ref-type="bibr">8</xref>). Sorafenib is an oral multikinase inhibitor targeting the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway, vascular endothelial growth factor receptors (VEGFR) and KIT, among other targets,<xref rid="R9" ref-type="bibr">9</xref> that provides nearly 3-month median survival benefit and a 31% reduction of risk of death in patients with advanced HCC.<xref rid="R3" ref-type="bibr">3</xref> Regorafenib displays more potent pharmacological activity than sorafenib and provided a 38% reduction of risk of death in patients progressing on sorafenib treatment.<xref rid="R5" ref-type="bibr">5 10</xref>
</p>
              <p>Several randomised studies testing adjuvant therapies such as interferon (IFN), chemotherapy, chemoembolisation, internal radiation, immune therapies and retinoids have failed to provide outcome benefits or led to inconclusive results and therefore are not recommended in clinical practice.<xref rid="R2" ref-type="bibr">2 11</xref> In this context, the STORM trial was designed to evaluate the efficacy and safety of sorafenib as an adjuvant therapy in patients with HCC with a complete radiological response following surgical resection or local ablation.<xref rid="R12" ref-type="bibr">12</xref> This phase 3, randomised, double-blind, placebo controlled trial included 1114 patients. The primary endpoint of recurrence-free survival (RFS) was not met (33.3 months in the sorafenib group vs 33.7 months in the placebo group; HR 0.94; 95% CI 0.78 to 1.13, p=0.26)<xref rid="R12" ref-type="bibr">12</xref> and therefore further research is required to identify strategies to prevent HCC recurrence.</p>
              <p>The mechanism of action of sorafenib includes inhibition of both MAPK/ERK-mediated cell proliferation and angiogenesis driven by VEGF signalling.<xref rid="R9" ref-type="bibr">9</xref> Moreover, it is known that sorafenib acts both on tumour cells as well as on endothelial cells.<xref rid="R9" ref-type="bibr">9</xref> Despite multiple studies, robust predictive biomarkers of response to sorafenib (including sorafenib targets such as MAPK/ERK or VEGF) in patients with HCC have not yet been identified. While sorafenib provides benefits across all subgroups of patients, a recent meta-analysis of individual data from the phase 3 SHARP and Asia-Pacific HCC trials showed that patients with HCV aetiology and liver only disease have a significantly greater benefit with sorafenib.<xref rid="R13" ref-type="bibr">13 14</xref> In terms of biomarkers, correlative analyses in the SHARP trial showed a non-significant trend towards higher survival benefit from sorafenib treatment in tumours with high c-Kit or low hepatocyte growth factor (HGF) plasma concentration.<xref rid="R15" ref-type="bibr">15</xref> Nonetheless, no biomarker has been identified to clearly predict sorafenib efficacy. In this scenario, a thorough analysis of biomarker-defined subpopulations that might benefit from sorafenib in the adjuvant setting is required.</p>
              <p>Herein we used a cohort derived from the phase 3 STORM trial population to conduct a companion biomarker analysis aimed at identifying biomarkers predicting sorafenib efficacy in preventing recurrence of HCC (hereafter, predictive biomarkers) and factors independently associated with prognosis (hereafter, prognostic biomarkers). Because our biomarker study was conducted on specimens collected in a randomised controlled trial (RCT) and were assayed after trial completion, our results hold a level B of evidence.<xref rid="R16" ref-type="bibr">16</xref> This level of evidence goes beyond observational or retrospective biomarker studies (levels C and D) and is the closest to an RCT specifically designed to address tumour marker value as a predictor of outcome (level A).<xref rid="R16" ref-type="bibr">16</xref>
</p>
            </sec>
            <sec sec-type="methods" id="s2">
              <title>Materials and methods</title>
              <sec id="s2a">
                <title>Tumour samples</title>
                <p>Formalin-fixed paraffin-embedded (FFPE) tissue blocks from patients with HCC resected between 2008 and 2010 and randomised into treatment in the STORM clinical trial (NCT00692770)<xref rid="R12" ref-type="bibr">12</xref> were collected from the highest enrolling centres after ad hoc institutional review board clearance (online <xref ref-type="supplementary-material" rid="SP1">supplementary table 1</xref>). Out of the 202 collected samples, 188 were suitable for the study (hereinafter, BIOSTORM cohort) (<xref ref-type="fig" rid="F1">figure 1</xref>). See also online <xref ref-type="supplementary-material" rid="SP2">supplementary materials and methods</xref>.</p>
                <supplementary-material content-type="local-data" id="SP1">
                  <object-id pub-id-type="doi">10.1136/gutjnl-2018-316408.supp1</object-id>
                  <label>Supplementary data</label>
                  <p>
                    <inline-supplementary-material id="ss1" xlink:href="gutjnl-2018-316408supp001.pdf" mimetype="application" mime-subtype="pdf" content-type="local-data"/>
                  </p>
                </supplementary-material>
                <supplementary-material content-type="local-data" id="SP2">
                  <object-id pub-id-type="doi">10.1136/gutjnl-2018-316408.supp2</object-id>
                  <label>Supplementary data</label>
                  <p>
                    <inline-supplementary-material id="ss2" xlink:href="gutjnl-2018-316408supp002.pdf" mimetype="application" mime-subtype="pdf" content-type="local-data"/>
                  </p>
                </supplementary-material>
                <fig id="F1" orientation="portrait" position="float">
                  <label>Figure 1</label>
                  <caption>
                    <p>Flow chart of the BIOSTORM study. FISH, fluorescence in situ hybridisation; IHC, immunohistochemistry; VEGFA, vascular endothelial growth factor A.</p>
                  </caption>
                  <graphic xlink:href="gutjnl-2018-316408f01"/>
                </fig>
              </sec>
              <sec id="s2b">
                <title>Immunohistochemistry, fluorescence in situ hybridisation, whole transcriptome analysis and targeted exome sequencing</title>
                <p>See online <xref ref-type="supplementary-material" rid="SP2">supplementary materials and methods</xref>.</p>
              </sec>
              <sec id="s2c">
                <title>Endpoints, clinical data and statistical analysis</title>
                <p>RFS was defined as the time from randomisation to the first documented disease recurrence by independent radiological assessment or death by any cause, whichever happened first. The primary endpoint was to identify biomarkers predicting sorafenib efficacy in preventing HCC recurrence in terms of RFS. The secondary endpoint was to define prognostic biomarkers of RFS and/or validate those previously reported. In the BIOSTORM cohort, all events were recurrences (70 RFS events in 188 patients), and thus time to progression was equivalent to RFS. Biomarkers were considered predictive of sorafenib efficacy in preventing HCC recurrence when p of interaction was &lt;0.05. Patients who had undergone less than one treatment cycle (4 weeks) were excluded from the predictive biomarker analysis (sorafenib: n=9 out of 83; placebo: n=6 out of 105). All statistical tests were two sided. Data were analysed with SPSS V.23.0 (SPSS) and the R statistical package. See also online <xref ref-type="supplementary-material" rid="SP2">supplementary materials and methods</xref>.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="s3">
              <title>Results</title>
              <sec id="s3a">
                <title>Baseline and clinical characteristics of the BIOSTORM cohort</title>
                <p>The BIOSTORM cohort consists of a subgroup of 188 patients representing 21% of the 900 STORM patients who had been treated with surgical resection. From those, 83 had been treated with sorafenib and 105 with placebo. All baseline patient demographics and disease characteristics were balanced in both BIOSTORM treatment groups (<xref rid="T1" ref-type="table">table 1</xref>). In addition, most BIOSTORM clinical-pathologic characteristics were similar to the STORM cohort, which only differed in age (p&lt;0.001), prevalence of hepatitis C (p&lt;0.001) and microvascular invasion (p=0.003).</p>
                <table-wrap id="T1" orientation="portrait" position="float">
                  <label>Table 1</label>
                  <caption>
                    <p>Baseline patient demographics and disease characteristics by treatment group within BIOSTORM and compared with the STORM population undergoing resection</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <td valign="bottom" rowspan="2" align="left" colspan="1"/>
                        <td valign="bottom" colspan="2" align="left" rowspan="1">BIOSTORM (n=188)</td>
                        <td valign="bottom" rowspan="2" align="left" colspan="1">STORM (n=900)</td>
                      </tr>
                      <tr>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">Sorafenib (n=83)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">Placebo (n=105)</td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">Age (years), median (range)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">63 (34–82)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">61 (26–84)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">58 (19–83)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> ≥65 years, n (%)*</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">39 (47.0)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">45 (42.9)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">267 (29.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" colspan="4" align="left" rowspan="1">Sex, n (%)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> Male</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">74 (89.2)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">92 (87.6)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">743 (82.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> Female</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">9 (10.8)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">13 (12.4)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">157 (17.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" colspan="4" align="left" rowspan="1">Race, n (%)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> Asian</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">61 (73.5)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">70 (66.7)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">605 (67.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> White</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">20 (24.1)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">34 (32.4)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">255 (28.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> Other</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">2 (2.4)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">1 (1.0)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">40 (4.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" colspan="4" align="left" rowspan="1">Region, n (%)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> Americas (North, South)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">6 (7.2)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">8 (7.6)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">102 (11.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> Asia-Pacific (including Australia, New Zealand)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">56 (67.5)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">68 (64.8)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">574 (63.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> Europe</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">21 (25.3)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">29 (27.6)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">224 (24.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" colspan="4" align="left" rowspan="1">Aetiology, n (%)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> Hepatitis B only*</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">38 (45.8)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">42 (40.0)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">486 (54.0)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> Hepatitis C only*</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">24 (28.9)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">37 (35.2)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">177 (19.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> Alcohol only</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">5 (6.0)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">6 (5.7)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">61 (6.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> Unknown</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">15 (18.1)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">13 (12.4)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">120 (13.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> Other</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">1 (1.2)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">7 (6.7)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">56 (6.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" colspan="4" align="left" rowspan="1">BCLC stage, n (%)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> Very early stage (0)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">6 (7.2)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">8 (7.6)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> Early stage (A)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">77 (92.8)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">97 (92.4)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" colspan="4" align="left" rowspan="1">Number of lesions, n (%)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> 1</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">73 (88.0)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">99 (94.3)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">851 (94.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> 2</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">9 (10.8)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">5 (4.8)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">41 (4.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> ≥3</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">1 (1.2)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">1 (1.0)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">8 (0.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">Maximum tumour size (mm), median (range)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">39 (12–145)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">35 (16–175)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">40 (10–200)</td>
                      </tr>
                      <tr>
                        <td valign="top" colspan="4" align="left" rowspan="1">Microscopic vascular invasion, n (%)†</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> No</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">49 (59.0)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">54 (51.4)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">607 (67.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> Yes*</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">33 (39.8)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">48 (45.7)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">293 (32.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">Tumour satellites, n (%)†</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1"/>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1"/>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> No</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">77 (92.8)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">96 (91.4)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">819 (91.0)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> Yes</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">5 (6.0)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">6 (5.7)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">81 (9.0)</td>
                      </tr>
                      <tr>
                        <td valign="top" colspan="4" align="left" rowspan="1">Histological grade, n (%)‡</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> 1</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">15 (18.1)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">17 (16.2)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">154 (17.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> 2</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">53 (63.9)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">67 (63.8)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">576 (64.0)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> 3</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">15 (18.1)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">20 (19.0)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">169 (18.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">Risk of recurrence, n (%)†</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1"/>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1"/>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> Intermediate</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">35 (42.2)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">45 (42.9)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">470 (52.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> High*</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">47 (56.6)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">57 (54.3)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">430 (47.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">Months resection to random, median (range)§</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">1.8 (1.4–3.9)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">1.8 (1.3–7.2)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">2.6</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">Liver cirrhosis present, n (%)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">48 (57.8)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">58 (55.2)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">513 (57.0)</td>
                      </tr>
                      <tr>
                        <td valign="top" colspan="4" align="left" rowspan="1">Child-Pugh, n (%)¶</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> 5</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">68 (81.9)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">85 (81.0)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">716 (79.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> 6</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">14 (16.9)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">19 (18.1)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">161 (17.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1"> 7</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">1 (1.2)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">1 (1.0)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">19 (2.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">Albumin (g/dL), median (range)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">4.0 (2.9–4.7)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">4.0 (2.8–5.1)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">3.9</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">Total bilirubin (mg/dL), median (range)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">0.5 (0.2–2)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">0.6 (0.2–2.3)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">0.6</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">AFP (ng/mL), median (range)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">5.2 (1.8–313.6)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">5.8 (1.3–239.7)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">5.2</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tblfn1">
                      <p>High risk of recurrence was considered if patients had either one tumour of any size plus microvascular invasion, satellite tumours, or poorly differentiated microscopic appearance, or two or three tumours each 3 cm or smaller in size. An intermediate risk was defined as a single tumour of 2 cm or larger with well-differentiated or moderately differentiated microscopic appearance, and the absence of microvascular invasion or satellite tumours. Presence of liver cirrhosis was determined according to Case Report Form.</p>
                    </fn>
                    <fn id="tblfn2">
                      <p>*P&lt;0.05 for comparisons between patients in BIOSTORM and STORM cohorts.</p>
                    </fn>
                    <fn id="tblfn3">
                      <p>†Not available in four patients in BIOSTORM.</p>
                    </fn>
                    <fn id="tblfn4">
                      <p>‡Not available in one patient in BIOSTORM and STORM.</p>
                    </fn>
                    <fn id="tblfn5">
                      <p>§Months diagnosis to randomisation in STORM trial.</p>
                    </fn>
                    <fn id="tblfn6">
                      <p>¶Four patients in STORM trial had Child-Pugh 8.</p>
                    </fn>
                    <fn id="tblfn7">
                      <p>AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer Group.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>In BIOSTORM, as in STORM, median duration of treatment was shorter in sorafenib-treated patients compared with placebo (17 vs 30.6 months; p=0.007). Follow-up was shorter in sorafenib patients compared with placebo (30.9 vs 41.8 months; p&lt;0.001), partially due to a higher rate of treatment discontinuation. In BIOSTORM, median RFS in placebo arm was 42.0 months and was not reached with sorafenib. Moreover, no significant benefit of sorafenib on RFS was observed (HR=0.82; 95% CI 0.50 to 1.35; p=0.430) (online <xref ref-type="supplementary-material" rid="SP3 SP4">supplementary figure 1</xref>). This was consistent with the STORM subgroup analysis of patients undergoing resection (HR=0.94; 95% CI 0.76 to 1.16).</p>
              </sec>
              <sec id="s3b">
                <title>Molecular factors predicting benefit to sorafenib</title>
                <p>None of the baseline clinical variables (summarised in <xref rid="T1" ref-type="table">table 1</xref>) such as microvascular invasion (p=0.164) or presence of satellites (p=0.627) predicted response to sorafenib by p of interaction test. Thus, we explored molecular variables from MAPK pathway, VEGF pathway and previously reported molecular signatures and drivers to assess their predictive capacity.</p>
                <sec id="s3b1">
                  <title>MAPK pathway</title>
                  <p>Given that sorafenib is a multikinase inhibitor that targets predominantly pathways involved in proliferation and neoangiogenesis, we sought to explore the predictive capability of different members of the MAPK pathway and VEGF signalling.</p>
                  <p>It is well known that the RAS/RAF/MAPK/ERK cascade plays a role in the regulation of cell proliferation, survival and differentiation,<xref rid="R17" ref-type="bibr">17</xref> and phosphorylated extracellular signal-regulated kinase (pERK) is a commonly used surrogate of MAPK pathway activation. In BIOSTORM, nuclear and cytoplasmic pERK staining was observed in tumour hepatocytes in 11% of the patients (n=20/175), whereas it was identified in 86% of patients in tumour-associated endothelial cells (n=150/175) (<xref ref-type="fig" rid="F2">figure 2A,B</xref>). These results were consistent with our previous data.<xref rid="R18" ref-type="bibr">18</xref> Tumours with positive pERK hepatocyte staining significantly correlated with the proliferative marker Ki67 (p=0.048) (online <xref ref-type="supplementary-material" rid="SP3 SP5">supplementary figure 2</xref>). In terms of clinical-pathologic correlations, tumours displaying pERK hepatocyte staining were significantly associated with poorly differentiated tumours (p=0.002). In parallel, tumours with pERK-positive endothelial cells were smaller compared with pERK-negative cases (mean tumour size 41 vs 60 mm; p=0.033). Samples with negative pERK endothelial staining were positive for CD31 (online <xref ref-type="supplementary-material" rid="SP3 SP5">supplementary figure 2</xref>), suggesting that this negative staining was not due to absence of vascularisation.</p>
                  <fig id="F2" orientation="portrait" position="float">
                    <label>Figure 2</label>
                    <caption>
                      <p>Representative examples of (A) immunohistochemical pERK staining of tumour hepatocytes, (B) pERK staining of tumour endothelial cells, and (C, D) pVEGFR2 positive and negative staining of tumour hepatocytes. (E, F) Representative images of fluorescence in situ hybridisation (FISH) staining to determine vascular endothelial growth factor A (VEGFA) copy number. VEGFA was labelled in red; the control reference Cep6 in green; and DAPI-stained cell nuclei in blue.</p>
                    </caption>
                    <graphic xlink:href="gutjnl-2018-316408f02"/>
                  </fig>
                  <p>To evaluate if pERK predicted RFS according to treatment allocation, we analysed the interaction between pERK and sorafenib effect. Sorafenib-treated patients with negative hepatocyte pERK staining (n=64/75, 85.3%) presented increased RFS compared with patients in the placebo group with negative hepatocyte pERK staining (median RFS not reached vs 42.1 months; HR=0.49; p=0.043), a difference that was not significantly better when compared with RFS of those patients with positive hepatocyte pERK staining (p of interaction p=0.11; online <xref ref-type="supplementary-material" rid="SP3 SP6">supplementary figure 3A</xref>). Neither endothelial pERK (p of interaction p=0.10; online <xref ref-type="supplementary-material" rid="SP3 SP6">supplementary figure 3B</xref>) nor Ki67 (p of interaction p=0.19) was predictive of sorafenib efficacy in terms of RFS. Also, the predictive value of additional previously reported candidate biomarkers,<xref rid="R15" ref-type="bibr">15</xref> such as expression levels of HGF, c-Kit, vascular endothelial growth factor A (VEGFA) and basic fibroblast growth factor/fibroblast growth factor 2 (bFGF/FGF2) did not retain significant predictive value.</p>
                </sec>
                <sec id="s3b2">
                  <title>VEGF signalling</title>
                  <p>We had previously identified focal chromosomal amplifications in the locus of <italic>VEGFA</italic>—the gene encoding for the VEGFR2 activating ligand—in approximately 7% of patients with HCC, as the second most prevalent focal amplification in HCC.<xref rid="R1" ref-type="bibr">1 19</xref> Retrospective studies have suggested that VEGFA gene copy number predicts response to sorafenib-treated patients in the adjuvant setting.<xref rid="R20" ref-type="bibr">20</xref> Thus, we analysed whether pVEGFR2—a surrogate of the proliferative VEGF pathway—or VEGFA levels predicted RFS in sorafenib-treated patients.</p>
                  <p>Immunohistochemical analysis of pVEGFR2 revealed two different patterns of staining: nuclear pVEGFR2 staining, detected in tumour hepatocytes in 36% of the patients (n=54/152) (<xref ref-type="fig" rid="F2">figure 2C,D</xref>), and cell membrane pVEGFR2 staining, detected only in 4% of the patients (n=6/152). Nuclear pVEGFR2 positively regulates the expression of the <italic>VEGFR2</italic> gene itself by interacting with the promoter region of the gene, and promotes endothelial cell growth and proliferation.<xref rid="R21" ref-type="bibr">21</xref> When tested for interaction with the treatment, absence of nuclear pVEGFR2 staining presented a non-significant trend for better RFS with sorafenib (p of interaction p=0.083) (online <xref ref-type="supplementary-material" rid="SP3 SP6">supplementary figure 3C</xref>). Membrane pVEGFR2 was not tested because of the limited number of samples displaying this staining.</p>
                  <p>On the other hand, analysis of <italic>VEGFA</italic> copy number demonstrated that high-level gains of this gene (≥4 copies) were present in 10% of the patients (n=17/162) (<xref ref-type="fig" rid="F2">figure 2E,F</xref>), consistent with our previous observations.<xref rid="R19" ref-type="bibr">19</xref> Nonetheless, high-level gains of <italic>VEGFA</italic> did not correlate with recurrence prevention in sorafenib-treated patients (p of interaction p=0.938) (online <xref ref-type="supplementary-material" rid="SP3 SP6">supplementary figure 3D</xref>). Tumours with satellites (p&lt;0.001) and microvascular invasion (p=0.019) were significantly enriched with <italic>VEGFA</italic> focal amplifications.</p>
                </sec>
                <sec id="s3b3">
                  <title>Reported molecular signatures and driver genes</title>
                  <p>To further investigate candidate predictive biomarkers, we analysed whole-genome expression. We obtained transcriptomic data for 140 HCC samples and 90 non-tumour adjacent tissues. The transcriptomic profile of each sample was used to classify each tumour according to its molecular class, and to assess enrichment of signalling pathways, progenitor features and clinical characteristics. Around 40% of the patients belong to the proliferation subclass<xref rid="R19" ref-type="bibr">19</xref> (n=53/140) (online <xref ref-type="supplementary-material" rid="SP1">supplementary table 2</xref>), as observed in other HCC cohorts. This group of tumours was significantly enriched in S1 subclass (p&lt;0.001),<xref rid="R22" ref-type="bibr">22</xref> aberrant activation of tyrosine-protein kinase Met or hepatocyte growth factor receptor (MET)<xref rid="R23" ref-type="bibr">23</xref> (p=0.038), late transforming growth factor beta (TGFβ)<xref rid="R24" ref-type="bibr">24</xref> (p=0.009), insulin-like growth factor 1 receptor (IGF1R)<xref rid="R25" ref-type="bibr">25</xref> (p&lt;0.001), Notch<xref rid="R26" ref-type="bibr">26</xref> (p&lt;0.001), mechanistic target of rapamycin (mTOR)<xref rid="R27" ref-type="bibr">27</xref> (p&lt;0.001), and gene signatures associated with recurrence<xref rid="R28" ref-type="bibr">28</xref> (p=0.015), vascular invasion<xref rid="R29" ref-type="bibr">29</xref> (p&lt;0.001) and sorafenib resistance<xref rid="R30" ref-type="bibr">30</xref> (p=0.002). Of note, tumours displaying pERK-positive hepatocytes were enriched in proliferation-related signatures (IGF1R<xref rid="R25" ref-type="bibr">25</xref> (p&lt;0.001), Notch<xref rid="R26" ref-type="bibr">26</xref> (p&lt;0.001), Cytokeratin 19 (CK19)<xref rid="R31" ref-type="bibr">31</xref> (p=0.015) and G2<xref rid="R32" ref-type="bibr">32</xref> (p=0.004)) (online <xref ref-type="supplementary-material" rid="SP1">supplementary table 3</xref>). On the other hand, patients in the non-proliferation class<xref rid="R19" ref-type="bibr">19</xref> (45%, n=63/140) were significantly associated with S3 subclass<xref rid="R22" ref-type="bibr">22</xref> (p&lt;0.001).</p>
                  <p>In terms of prediction, we tested 22 previously reported tumour-derived molecular signatures, and survival prognostic signatures generated from adjacent non-tumour samples capturing the microenvironment signalling (online <xref ref-type="supplementary-material" rid="SP1">supplementary table 2</xref>).<xref rid="R31" ref-type="bibr">31 33 34</xref> None of them showed predictive capacity in terms of RFS (equivalent to recurrence) in the interaction analysis. This applies to signatures designed for/or associated to recurrence<xref rid="R24" ref-type="bibr">24 28 32</xref> or survival<xref rid="R33" ref-type="bibr">33 34</xref> in retrospective analysis. Finally, the prognostic capacity of survival of gene signatures was not tested due to the marginal number of events (24/188).</p>
                  <p>Further, we explored the mutational landscape of the BIOSTORM cohort using targeted exome sequencing to identify mutations in 19 known HCC drivers<xref rid="R1" ref-type="bibr">1</xref> (online <xref ref-type="supplementary-material" rid="SP1">supplementary table 4</xref>; online <xref ref-type="supplementary-material" rid="SP3 SP7">supplementary figure 4</xref>). The mutational profile was similar to what has been previously reported for HCC drivers,<xref rid="R1" ref-type="bibr">1</xref> with TERT promoter mutations (53%), <italic>TP53</italic> (46%), <italic>CTNNB1</italic> (21%) and <italic>AXIN1</italic> (16%) as the four most prevalent mutations in our cohort (online <xref ref-type="supplementary-material" rid="SP1">supplementary table 4</xref>). No significant association was found between mutational profile and outcome in terms of RFS and treatment.</p>
                </sec>
              </sec>
              <sec id="s3c">
                <title>Novel 146-gene expression signature predicts role of sorafenib in prevention of recurrence</title>
                <p>Given the lack of interaction between tested clinical and biomarker candidates and treatment benefit, we developed a gene expression signature able to predict the role of sorafenib in recurrence prevention of HCC in resected patients.</p>
                <p>Using standard procedures, we first identified genes associated with prognosis (Cox score p&lt;0.05) in terms of RFS in the set of 67 sorafenib-treated patients and in the set of 73 placebo-treated patients (<xref ref-type="fig" rid="F1">figure 1</xref>). To exclude genes that were mainly associated with poor prognosis independently of treatment, we filtered out those genes identified with the same prognosis value in both cohorts, keeping only those exclusively detected in the sorafenib group. We obtained a 146-gene set able to discriminate precisely patients benefiting from sorafenib in terms of extended RFS (from herein referred to as ‘<italic>sorafenib RFS responders</italic>’) from patients where sorafenib had no effect (‘<italic>non-responders</italic>’) (<xref ref-type="fig" rid="F3">figure 3</xref>). This gene signature was composed of 87 poor prognosis genes and 59 good prognosis genes (<xref ref-type="fig" rid="F3">figure 3A</xref> and online <xref ref-type="supplementary-material" rid="SP1">supplementary table 5</xref>). The signature identified 30% of the patients (n=42/140) as ‘<italic>sorafenib RFS</italic> responders’. These patients did not reach median RFS with sorafenib, while ‘non-responders’ presented a median RFS of 28 months. The predictive value of the signature was statistically significant (p of interaction p=0.040) in the BIOSTORM cohort (<xref ref-type="fig" rid="F3">figure 3B</xref>).</p>
                <fig id="F3" orientation="portrait" position="float">
                  <label>Figure 3</label>
                  <caption>
                    <p>Novel 146-gene signature associated with better recurrence-free survival (RFS) in sorafenib-treated patients. (A) 146-gene signature identifying BIOSTORM patients with better RFS when treated with sorafenib. (B) Kaplan-Meier estimates measuring RFS probability over time of patients identified by the 146-gene signature capturing recurrence prevention in individuals treated with sorafenib (in blue) or placebo (in orange). P value of biomarker treatment interaction was 0.040. Left panel shows the Kaplan-Meier estimates for patients identified as ‘<italic>sorafenib RFS responders</italic>’ by the gene signature, and the right panel, the estimates for those identified as ‘<italic>non-responders</italic>’. (C) Patients identified by the 146-gene signature as ‘<italic>sorafenib RFS responders</italic>’ (in green) displayed downregulation of KRAS and JAK/STAT signalling. In contrast, patients recognised as ‘<italic>non-responders</italic>’ (in red) were enriched in MAPK, mTOR, IGF1R and Notch signalling.</p>
                  </caption>
                  <graphic xlink:href="gutjnl-2018-316408f03"/>
                </fig>
                <p>We characterised ‘<italic>sorafenib RFS responders</italic>’ and ‘<italic>non-responders</italic>’ at the molecular level using enrichment analysis tools (<xref ref-type="fig" rid="F3">figure 3C</xref>). In brief, ‘<italic>sorafenib RFS responders’</italic> showed (A) downregulation of pathways indicative of poor prognosis such as KRAS, (B) activation of EIF2 signalling—previously reported to be inhibited after sorafenib treatment<xref rid="R9" ref-type="bibr">9</xref>—and oxidative stress responses, (C) association with immune-related processes, such as T helper cell differentiation and B cell development, and (D) upregulation of bile acid and lipid metabolism-related pathways (ie, liver X receptor signalling and related farnesoid X receptor/retinoid X receptor) (online <xref ref-type="supplementary-material" rid="SP8">supplementary tables 6–8</xref>). All these molecular traits were also present in the non-tumour adjacent tissue (online <xref ref-type="supplementary-material" rid="SP8">supplementary tables 7 and 8</xref>). Conversely, ‘<italic>non-responders’</italic> (98/140; 70%) were characterised by (A) activation of signalling pathways of poor outcome (PI3K-AKT-mTOR, KRAS, MAPK, IGF1R, Notch); (B) higher mRNA alpha-fetoprotein levels (p=0.03); and (C) microvascular invasion (p=0.042) and HCV-related HCC (p&lt;0.001) (<xref ref-type="fig" rid="F3">figure 3C</xref>, online <xref ref-type="supplementary-material" rid="SP3 SP9">supplementary figure 5C</xref> and online <xref ref-type="supplementary-material" rid="SP1 SP8">supplementary tables 6–9</xref>). Of note, the mutational profile of known oncogenes in HCC was not significantly different in ‘<italic>sorafenib RFS responders</italic>’ when compared with ‘<italic>non-responders</italic>’.</p>
                <supplementary-material content-type="local-data" id="SP8">
                  <object-id pub-id-type="doi">10.1136/gutjnl-2018-316408.supp8</object-id>
                  <label>Supplementary data</label>
                  <p>
                    <inline-supplementary-material id="ss8" xlink:href="gutjnl-2018-316408supp008.xlsx" mimetype="application" mime-subtype="xlsx" content-type="local-data"/>
                  </p>
                </supplementary-material>
              </sec>
              <sec id="s3d">
                <title>Immune cell profiles in ‘sorafenib <italic>RFS</italic> responders’</title>
                <p>Recent preclinical studies have suggested that sorafenib may exert immune-modulating effects on the tumour microenvironment of HCC through upregulation of T cell activity, inhibition of macrophage-induced tumour growth and activation of natural killer (NK) cells.<xref rid="R35" ref-type="bibr">35–37</xref> Therefore, it is important to understand the immune profile of ‘<italic>sorafenib RFS responders’</italic> tumours. To this end, we characterised the immune infiltrates of the BIOSTORM tumours using published gene signatures<xref rid="R38" ref-type="bibr">38</xref> and data deconvolution methods (ie, Cibersort),<xref rid="R39" ref-type="bibr">39</xref> and correlated the results with the prediction of the 146-gene signature and our recently reported <italic>HCC Immune class</italic>.<xref rid="R38" ref-type="bibr">38</xref> In this regard, we have defined that ~30% of HCCs present an ‘inflamed’ microenvironment (so-called <italic>Immune class</italic>) with high infiltration of immune cells, adaptive T cell response, active IFN-γ signalling and markers of cytolytic activity.<xref rid="R38" ref-type="bibr">38</xref> The <italic>Immune class</italic> did not directly predict recurrence or response to sorafenib.</p>
                <p>Here, our results indicate that the immune profile of ‘<italic>sorafenib RFS responder</italic>’ patients (n=42/140, 30%) was characterised by enrichment of signatures capturing the presence of B cells and CD4<sup>+</sup> T cells and derivatives (type 1 and 2 T helper cells, and follicular helper T cells); and the exclusion of <italic>Immune class</italic>-associated features (ie, CD8<sup>+</sup> T cells, effector memory T cells, and central memory T cells and tumour-associated tertiary lymphoid structures (TLS), generated during chronic immune stimulation to support infiltration and activation of the adaptive immune cells) (<xref ref-type="fig" rid="F4">figure 4</xref>). Furthermore, the innate immune profile of ‘<italic>sorafenib RFS responders</italic>’ was enriched in activated Mast cells and cytolytic NK cells (NK<sup>CD56dim</sup>), and showed absence of activated macrophages, components from the major histocompatibility complex, and downregulation of signal transducer and activator of transcription proteins and focal adhesion kinase 1/protein tyrosine kinase 2 (FAK1/PTK2) (<xref ref-type="fig" rid="F4">figure 4</xref>, online <xref ref-type="supplementary-material" rid="SP9 SP10">supplementary figures 5 and 6</xref>).<xref rid="R39" ref-type="bibr">39</xref> In addition, ‘<italic>sorafenib RFS responders</italic>’ had significantly lower immunophenoscore—which has been associated with response to checkpoint blockade—and downregulation of IFN gene signatures predicting response to checkpoint inhibitors in other cancers (<xref ref-type="fig" rid="F4">figure 4</xref>).<xref rid="R39" ref-type="bibr">39–41</xref>
</p>
                <fig id="F4" orientation="portrait" position="float">
                  <label>Figure 4</label>
                  <caption>
                    <p>Heatmap displaying the molecular class and immune characteristics of ‘<italic>sorafenib RFS responders</italic>’ and ‘<italic>non-responders</italic>’. Differences in RFS profiles in the sorafenib and placebo-treated patients identified by the signature as ‘<italic>sorafenib RFS responders</italic>’ suggest that placebo patients could have been candidates to respond to sorafenib. Immune profile of ‘<italic>sorafenib RFS responders</italic>’ highlights absence of CD8<sup>+</sup> T cell lymphocytes but enrichment of other adaptive immune elements such as B cells and CD4<sup>+</sup> T cells and derivatives. P values describe differences between ‘<italic>sorafenib RFS responders</italic>’ and ‘<italic>non-responders</italic>’. #P&lt;0.01 between ‘<italic>sorafenib RFS responders</italic>’ and HCCs of ‘<italic>Immune class</italic>’. Signatures are referenced in online <xref ref-type="supplementary-material" rid="SP1">supplementary table 11</xref>. HCC, hepatocellular carcinoma; IFN, interferon; MHC, major histocompatibility complex; NK, natural killer cells; ns, non-significant differences; RFS, recurrence-free survival; TLS, tertiary lymphoid structures.</p>
                  </caption>
                  <graphic xlink:href="gutjnl-2018-316408f04"/>
                </fig>
                <p>On the other hand, ‘<italic>non-responders</italic>’ (98/140; 70%) encompassed a subgroup of HCCs imprinted with <italic>Immune class</italic> traits (27/98; 28%), characterised by CD8<sup>+</sup> T cells, TLS and programmed cell death protein 1 (PD1) signalling, along with another subgroup of HCCs characterised by <italic>Immune exclusion</italic> (<italic>CTNNB1</italic> class: 27/98; 28%)<xref rid="R38" ref-type="bibr">38</xref> (<xref ref-type="fig" rid="F4">figure 4</xref>).</p>
              </sec>
              <sec id="s3e">
                <title>Prognostic biomarkers of HCC recurrence</title>
                <p>The second aim of the study was to assess the prognostic value in terms of RFS of all above described clinical and molecular features. In the univariate analyses, positive hepatocyte pERK (HR=2.46; p=0.003) and nuclear pVEGFR2 (HR=1.84; p=0.022) were significantly associated with poor RFS (<xref ref-type="fig" rid="F5">figure 5</xref>). In addition, three gene signatures (G3<xref rid="R32" ref-type="bibr">32</xref> enriched in cell cycle control genes (HR=1.73; p=0.049); MET<xref rid="R23" ref-type="bibr">23</xref> (HR=2.28; p=0.017); and IFN1α<xref rid="R42" ref-type="bibr">42</xref> (HR=2.09; p=0.019)) were associated with poor RFS (<xref rid="T2" ref-type="table">table 2</xref> and online <xref ref-type="supplementary-material" rid="SP1">supplementary table 10</xref>). Previously reported gene signatures from tumour and adjacent tissue designed to predict survival<xref rid="R33" ref-type="bibr">33 34</xref> or recurrence<xref rid="R24" ref-type="bibr">24 28 32</xref> did not predict RFS in the current study (online <xref ref-type="supplementary-material" rid="SP1">supplementary table 10</xref>). In the multivariate model, only hepatocyte pERK staining and microvascular invasion retained independent prognostic value for RFS (<xref rid="T2" ref-type="table">table 2</xref>). Both biomarkers were associated with poor prognosis (pERK HR=2.41; 95% CI 1.21 to 4.80; vascular invasion HR=2.09; 95% CI 1.14 to 3.83).</p>
                <fig id="F5" orientation="portrait" position="float">
                  <label>Figure 5</label>
                  <caption>
                    <p>Prognostic value of hepatocyte pERK and pVEGFR2. Tumours with hepatocyte pERK staining (A) or pVEGFR2 staining (B) have significantly poorer outcome compared with pERK negative or pVEGFR2 tumours.</p>
                  </caption>
                  <graphic xlink:href="gutjnl-2018-316408f05"/>
                </fig>
                <table-wrap id="T2" orientation="portrait" position="float">
                  <label>Table 2</label>
                  <caption>
                    <p>Univariate and multivariate analysis of clinical and molecular prognostic factors in terms of RFS</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <td rowspan="2" align="left" colspan="1"/>
                        <td rowspan="2" align="left" colspan="1">Patients (%)</td>
                        <td valign="bottom" colspan="2" align="left" rowspan="1">Univariate</td>
                        <td valign="bottom" colspan="2" align="left" rowspan="1">Multivariate</td>
                      </tr>
                      <tr>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">HR (95% CI)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">P values</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">HR (95% CI)</td>
                        <td valign="bottom" align="left" rowspan="1" colspan="1">P values</td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">Liver cirrhosis (present vs absent)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">106 (56)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">1.64 (1.00 to 2.69)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">0.049</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1">NS</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">Microscopic vascular invasion (yes vs no)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">81 (44)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">1.87 (1.16 to 3.00)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">0.010</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">2.09 (1.14 to 3.83)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">
                          <bold>0.017</bold>
                        </td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">Aetiology (hepatitis C vs others)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">61 (32)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">1.70 (1.06 to 2.73)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">0.028</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1">NS</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">Hepatocyte pERK (positive vs negative)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">20 (11)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">2.46 (1.36 to 4.44)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">0.003</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">2.41 (1.21 to 4.80)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">
                          <bold>0.012</bold>
                        </td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">pVEGFR2 (positive vs negative)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">54 (36)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">1.84 (1.09 to 3.09)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">0.022</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1">NS</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">G3 (present vs absent)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">43 (31)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">1.73 (1.00 to 3.00)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">0.049</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1">NS</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">MET (present vs absent)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">18 (13)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">2.28 (1.16 to 4.47)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">0.017</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1">NS</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" rowspan="1" colspan="1">Response to IFNα1 (present vs absent)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">24 (17)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">2.09 (1.13 to 3.87)</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1">0.019</td>
                        <td valign="top" align="char" char="." rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1">NS</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tblfn8">
                      <p>The univariate analysis was conducted for 33 variables, including <italic>clinicopathological variables</italic> (liver cirrhosis, microscopic vascular invasion, aetiology, multinodularity, maximum tumour size (threshold 50 mm), tumour satellites, histological grade (3 vs 1–2)), <italic>molecular traits</italic> (hepatocyte pERK, endothelial pERK, nuclear pVEGFR2 and VEGFA) and 22 <italic>gene signatures</italic> (online <xref ref-type="supplementary-material" rid="SP1">supplementary table 10</xref>). In the multivariate analysis, only microscopic vascular invasion and hepatocyte pERK retained independent prognostic value.</p>
                    </fn>
                    <fn id="tblfn9">
                      <p>IFN, interferon; NS, non-significant; RFS, recurrence-free survival; VEGFA, vascular endothelial growth factor A.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
            </sec>
            <sec sec-type="discussion" id="s4">
              <title>Discussion</title>
              <p>The success of sorafenib to inhibit tumour cell proliferation and angiogenesis<xref rid="R43" ref-type="bibr">43</xref> and its proven efficacy in advanced HCC<xref rid="R3" ref-type="bibr">3</xref> provided the rationale for testing this compound as adjuvant therapy to prevent recurrence after resection or local ablation. The phase 3 trial did not achieve the primary endpoint of superiority in RFS comparing sorafenib vs placebo. In the companion BIOSTORM study presented here, we explored biomarkers predicting the efficacy of sorafenib in preventing HCC recurrence, along with prognostic markers. Neither the proliferation or angiogenic biomarkers tested, nor the reported prognostic gene signatures or mutations identified in driver genes were associated with improved RFS in the sorafenib arm. The fact that none of the tested biomarkers predicted sorafenib RFS underscores the complexity of the mechanisms of action related to this drug. We generated a 146-gene signature able to identify 30% of patients who might benefit from sorafenib in terms of recurrence prevention. In addition, we further confirmed the role of pERK and microvascular invasion as two independent predictors of recurrence in early HCC. Previously reported gene signatures from tumour and adjacent tissue designed to predict survival<xref rid="R33" ref-type="bibr">33 34</xref> or recurrence<xref rid="R24" ref-type="bibr">24 28 32</xref> did not predict RFS in the current study. Our results hold a B level of evidence, which is based on subgroup or retrospective analysis of prospective phase 3 investigations.<xref rid="R16" ref-type="bibr">16</xref>
</p>
              <p>Thus far, more than 20 predictive biomarkers have entered clinical practice (eg, Her-2/neu expression as biomarker of response to trastuzumab; KRAS mutations for resistance to cetuximab or panitumumab).<xref rid="R44" ref-type="bibr">44–46</xref> For sorafenib, validated biomarkers of response have not yet been identified. A companion study of the SHARP trial described that plasma concentrations of soluble c-Kit and HGF showed a non-significant trend towards predicting response to sorafenib.<xref rid="R15" ref-type="bibr">15</xref> Several studies have proposed pERK, proxy of activation for the RAS/MAPK pathway inhibited by sorafenib in vitro and in solid tumours,<xref rid="R9" ref-type="bibr">9</xref> as a candidate biomarker associated to outcome after sorafenib treatment, though with contradictory results.<xref rid="R47" ref-type="bibr">47–49</xref> The absence of a validated scoring system for immunostaining for pERK, and the differences in detection methods, cohorts and endpoints could account for these inconsistencies. On the other hand, VEGF-related biomarkers have been proposed as potential predictors of response to sorafenib, considering that this drug inhibits pVEGFR2.<xref rid="R43" ref-type="bibr">43</xref> In this sense, VEGFA amplification was reported as a predictive factor of recurrence prevention in patients treated with sorafenib after liver resection.<xref rid="R20" ref-type="bibr">20</xref> However, all the above studies claiming the predictive value of pERK or VEGF-related molecules have been tested in the setting of retrospective non-randomised studies.</p>
              <p>In BIOSTORM, neither pERK, nor pVEGFR2 or VEGFA copy number status was significantly associated with recurrence prevention of sorafenib. Only sorafenib-treated patients tended towards better outcome if their tumours were hepatocyte-pERK negative and/or endothelial-pERK positive. Similarly, previously reported tumour-derived signatures associated with poor outcome in terms of recurrence or survival did not show predictive capacity for RFS on interaction analysis.</p>
              <p>Our generated signature identifying patients benefiting from sorafenib adjuvancy in terms of recurrence prevention classified 30% of cases as ‘<italic>sorafenib RFS responders</italic>’. These displayed downregulation of poor prognosis oncogenic pathways and deregulation of bile acid/lipid metabolism-related signalling, were enriched in B cells and CD4<sup>+</sup> T cells (and derivatives) and presented exclusion immune features related to the HCC <italic>Immune class</italic>,<xref rid="R38" ref-type="bibr">38</xref> and were associated to signatures of poor response to immune checkpoint inhibitors.<xref rid="R39" ref-type="bibr">39 41</xref> On the other hand, <italic>‘non-responders’</italic> tumours presented traits of cancer aggressiveness, with more vascular invasion and activation of poor prognosis signalling cascades, among others. The fact that HCV was more prevalent in <italic>non-responders</italic> does not align well with our previous report where HCV-related HCC had a better response to sorafenib in advanced cases.<xref rid="R14" ref-type="bibr">14</xref> Thus, clarification of this association would require further research.</p>
              <p>In terms of prognostic biomarkers, here we report pERK staining and microvascular invasion as two independent predictors of RFS in early HCC. While microvascular invasion is a well-established predictor of recurrence, the role of pERK is less documented. In our hands, patients displaying tumour pERK hepatocyte staining were characterised by poor differentiation degree and enhanced proliferation traits. pERK is a key element in angiogenesis and apoptosis. Nuclear pERK has been involved in proliferation processes, and the cytoplasmic form in cell differentiation. In the setting of early HCC, only one previous retrospective study reported a correlation between ERK activation and poor survival.<xref rid="R50" ref-type="bibr">50</xref> In terms of prognostic value of gene signatures, the univariate analysis revealed that three gene signatures (G3,<xref rid="R32" ref-type="bibr">32</xref> MET,<xref rid="R23" ref-type="bibr">23</xref> IFN1α<xref rid="R42" ref-type="bibr">42</xref>) predicted poor RFS, whereas previously reported gene signatures from tumour and adjacent tissue designed to predict survival<xref rid="R33" ref-type="bibr">33 34</xref> or recurrence<xref rid="R24" ref-type="bibr">24 28 32</xref> were not significantly associated with RFS. None of the above described signatures retained independent prognostic value in the multivariate analysis.</p>
              <p>Lastly, we acknowledge the strengths and limitations of the study. A major strength is that the study was conducted with a subgroup of patients randomised in the setting of the phase 3 STORM trial.<xref rid="R12" ref-type="bibr">12</xref> Therefore, BIOSTORM patients were prospectively followed, and management of adverse events, drug prescriptions and patients’ outcomes were properly scrutinised. In addition, the primary endpoint RFS (which in BIOSTORM study overlaps with time to recurrence) was assessed by central radiological reviewers. Finally, we used FFPE samples (standardised method of tissue processing) to ensure the highest preanalytical validity and followed standardised scoring criteria or, when absent, published criteria to ensure analytical validity. All these positive factors contrast with the conventional retrospective nature of most biomarker studies.<xref rid="R51" ref-type="bibr">51</xref> Moreover, our study follows the Reporting Recommendations for Tumor Marker guidelines,<xref rid="R52" ref-type="bibr">52</xref> and together with the SHARP biomarker investigation<xref rid="R15" ref-type="bibr">15</xref> is one of the few HCC studies for biomarker discovery with level B of evidence<xref rid="R16" ref-type="bibr">16</xref> (meaning retrospective study conducted in the setting of a randomised phase 3 trial). These types of studies have changed the standard of care in cases where the primary endpoint was negative, but the biomarker companion investigation yields positive results. This is the case of cetuximab for patients with colorectal cancer with <italic>wild-type</italic> RAS.<xref rid="R45" ref-type="bibr">45</xref> In terms of limitations, we acknowledge that despite a huge collecting effort, the number of patients recruited (n=188) is not ideal for defining bona fide predictive biomarkers.<xref rid="R16" ref-type="bibr">16</xref> This fact reinforces the need of budget allocation for ensuring the collection of tissue samples in the setting of controlled investigations in HCC.</p>
              <p>Overall, our biomarker BIOSTORM study (A) established lack of predictive value of sorafenib response for previously reported molecular biomarkers, (B) generated a predictive 146-gene signature to discriminate patients where sorafenib would prevent recurrence after resection, (C) established pERK and microvascular invasion as independent prognostic tools to identify recurrences in patients resected from early HCC tumours, and (D) did not validate previously reported signatures associated with recurrence.<xref rid="R24" ref-type="bibr">24 28 32</xref> For any of these biomarkers to be used as surrogates of efficacy of sorafenib recurrence prevention, a validation study using an independent cohort and conducted by independent investigators would be required.</p>
              <supplementary-material content-type="local-data" id="SP3">
                <object-id pub-id-type="doi">10.1136/gutjnl-2018-316408.supp3</object-id>
                <label>Supplementary data</label>
                <p>
                  <inline-supplementary-material id="ss3" xlink:href="gutjnl-2018-316408supp003.pdf" mimetype="application" mime-subtype="pdf" content-type="local-data"/>
                </p>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="SP4">
                <object-id pub-id-type="doi">10.1136/gutjnl-2018-316408.supp4</object-id>
                <label>Supplementary data</label>
                <p>
                  <inline-supplementary-material id="ss4" xlink:href="gutjnl-2018-316408supp004.jpg" mimetype="image" mime-subtype="jpeg" content-type="local-data"/>
                </p>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="SP5">
                <object-id pub-id-type="doi">10.1136/gutjnl-2018-316408.supp5</object-id>
                <label>Supplementary data</label>
                <p>
                  <inline-supplementary-material id="ss5" xlink:href="gutjnl-2018-316408supp005.jpg" mimetype="image" mime-subtype="jpeg" content-type="local-data"/>
                </p>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="SP6">
                <object-id pub-id-type="doi">10.1136/gutjnl-2018-316408.supp6</object-id>
                <label>Supplementary data</label>
                <p>
                  <inline-supplementary-material id="ss6" xlink:href="gutjnl-2018-316408supp006.jpg" mimetype="image" mime-subtype="jpeg" content-type="local-data"/>
                </p>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="SP7">
                <object-id pub-id-type="doi">10.1136/gutjnl-2018-316408.supp7</object-id>
                <label>Supplementary data</label>
                <p>
                  <inline-supplementary-material id="ss7" xlink:href="gutjnl-2018-316408supp007.jpg" mimetype="image" mime-subtype="jpeg" content-type="local-data"/>
                </p>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="SP9">
                <object-id pub-id-type="doi">10.1136/gutjnl-2018-316408.supp9</object-id>
                <label>Supplementary data</label>
                <p>
                  <inline-supplementary-material id="ss9" xlink:href="gutjnl-2018-316408supp009.jpg" mimetype="image" mime-subtype="jpeg" content-type="local-data"/>
                </p>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="SP10">
                <object-id pub-id-type="doi">10.1136/gutjnl-2018-316408.supp10</object-id>
                <label>Supplementary data</label>
                <p>
                  <inline-supplementary-material id="ss10" xlink:href="gutjnl-2018-316408supp010.jpg" mimetype="image" mime-subtype="jpeg" content-type="local-data"/>
                </p>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <p>We thank Marta Boteller, Judit Peix and Laia Cabellos for technical assistance and Juan José Lozano for suggestions in the transcriptomic analysis. This study has been in part developed at the building Centre Esther Koplowitz from IDIBAPS/CERCA Programme/Generalitat de Catalunya.</p>
            </ack>
            <fn-group>
              <fn fn-type="other">
                <p><bold>Contributors:</bold> RP, RM, LB, AV, ST, DS, AM, LRC, JC, MS, SNT and ZZ were involved in study concept and design; data acquisition, analysis and interpretation; manuscript drafting. TT, GYC, VM, SR, NK, HCL, EG, CV, AEC, UC, MM, LL, SS, JWP, CP and GM provided specimens for genomic analysis or clinical data, and critically revised the manuscript. JML and JB were involved in study concept and design; interpretation of data; critical revision of the manuscript; study supervision; and obtained funding.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Funding:</bold> This study was supported by Bayer HealthCare Pharmaceuticals and Onyx, a wholly owned subsidiary of Amgen. JML is supported by the European Commission (EC)/Horizon 2020 Program (HEPCAR, Ref 667273-2), US Department of Defense (CA150272P3), Asociación Española Contra el Cáncer (AECC), National Cancer Institute (P30-CA196521), Samuel Waxman Cancer Research Foundation, Spanish National Health Institute (SAF2016-76390) and the Generalitat de Catalunya/AGAUR (SGR-1162 and SGR-1358). JB has received grant support from Instituto de Salud Carlos III (ISCIII) (PI14/00962), AECC, AGAUR (SGR-605), WCR (AICR) 16-0026, and Spanish Health Ministry (Plan Estrategico Nacional contra la Hepatitis C). Centro de Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas is funded by ISCIII. RP and AM are funded by AECC and EC. ST, RM, LB and JC are supported by MINECO (BES-2014-068300), Río Hortega (ISCIII-SEOM), Beatriu de Pinós (AGAUR) and Miguel Servet (ISCIII-CP13/00160) grants, respectively. AV is supported by the US Department of Defense (CA150272P3), the Tisch Cancer Institute, and the American Association for the Study of Liver Diseases Foundation (AASLDF) Alan Hofmann Clinical and Translational Award.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p><bold>Competing interests:</bold> JML, JB, VM and AEC received research support and consultancy fees from Bayer. AV and SS received consultancy fees from Bayer. CP and GM are employees of Bayer HealthCare Pharmaceuticals.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Patient consent:</bold> Obtained.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Ethics approval:</bold> Hospital Clinic, Barcelona, Spain. Each participating centre obtained their own required institutional review board approval.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Correction notice:</bold> This article has been corrected since it published Online First. The abstract and significance of this study box has been updated as well as the patient consent statement.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Llovet</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Zucman-Rossi</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Pikarsky</surname><given-names>E</given-names></name>, <etal>et al</etal></person-group><article-title>Hepatocellular carcinoma</article-title>. <source>Nat Rev Dis Primers</source><year>2016</year>;<volume>2</volume>:<fpage>16018</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2016.18</pub-id><pub-id pub-id-type="pmid">27158749</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2</label>
                <mixed-citation publication-type="journal"><collab>European Association for the study of the liver</collab>. <article-title>EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. European Association for the Study of the Liver</article-title>. <source>J Hepatol</source><year>2018</year>;<volume>69</volume>:<fpage>182</fpage>–<lpage>236</lpage>.<pub-id pub-id-type="pmid">29628281</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Llovet</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Ricci</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Mazzaferro</surname><given-names>V</given-names></name>, <etal>et al</etal></person-group><article-title>Sorafenib in advanced hepatocellular carcinoma</article-title>. <source>N Engl J Med</source><year>2008</year>;<volume>359</volume>:<fpage>378</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa0708857</pub-id>
<pub-id pub-id-type="pmid">18650514</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kudo</surname><given-names>M</given-names></name></person-group><article-title>A randomised phase 3 trial of lenvatinib versus sorafenib in firstline treatment of patients with unresectable hepatocellular carcinoma</article-title>. <source>Lancet</source><year>2018</year>;<volume>391</volume>:<fpage>1163</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="pmid">29433850</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruix</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Qin</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Merle</surname><given-names>P</given-names></name>, <etal>et al</etal></person-group><article-title>Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial</article-title>. <source>Lancet</source><year>2017</year>;<volume>389</volume>:<fpage>56</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(16)32453-9</pub-id>
<pub-id pub-id-type="pmid">27932229</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abou-Alfa</surname><given-names>GK</given-names></name>, <name name-style="western"><surname>Meyer</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>AL</given-names></name>, <etal>et al</etal></person-group><article-title>Cabozantinib in patients with advanced and progressing hepatocellular carcinoma</article-title>. <source>N Engl J Med</source><year>2018</year>;<volume>379</volume>:<fpage>54</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1717002</pub-id>
<pub-id pub-id-type="pmid">29972759</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Khoueiry</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Sangro</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Yau</surname><given-names>T</given-names></name>, <etal>et al</etal></person-group><article-title>Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial</article-title>. <source>Lancet</source><year>2017</year>;<volume>389</volume>:<fpage>2492</fpage>–<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(17)31046-2</pub-id>
<pub-id pub-id-type="pmid">28434648</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kang</surname><given-names>YK</given-names></name>, <name name-style="western"><surname>Yen</surname><given-names>CJ</given-names></name>, <etal>et al</etal></person-group><article-title>A randomized, double-blind, placebo-controlled phase3 study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (ARP) following first-line sorafenib</article-title>. <source>J Clin Oncol</source><year>2018</year>;<volume>36</volume>(<issue>suppl; abstr 4003</issue>). <pub-id pub-id-type="doi">10.1093/annonc/mdw371.102</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilhelm</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Adnane</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Newell</surname><given-names>P</given-names></name>, <etal>et al</etal></person-group><article-title>Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling</article-title>. <source>Mol Cancer Ther</source><year>2008</year>;<volume>7</volume>:<fpage>3129</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-08-0013</pub-id>
<pub-id pub-id-type="pmid">18852116</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duffy</surname><given-names>AG</given-names></name>, <name name-style="western"><surname>Greten</surname><given-names>TF</given-names></name></person-group><article-title>Liver cancer: Regorafenib as second-line therapy in hepatocellular carcinoma</article-title>. <source>Nat Rev Gastroenterol Hepatol</source><year>2017</year>;<volume>14</volume>:<fpage>141</fpage>–<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1038/nrgastro.2017.7</pub-id>
<pub-id pub-id-type="pmid">28174418</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heimbach</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Kulik</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Finn</surname><given-names>RS</given-names></name>, <etal>et al</etal></person-group><article-title>AASLD guidelines for the treatment of hepatocellular carcinoma</article-title>. <source>Hepatology</source><year>2018</year>;<volume>67</volume>:<fpage>358</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1002/hep.29086</pub-id>
<pub-id pub-id-type="pmid">28130846</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruix</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Takayama</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Mazzaferro</surname><given-names>V</given-names></name>, <etal>et al</etal></person-group><article-title>Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet Oncol</source><year>2015</year>;<volume>16</volume>:<fpage>1344</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(15)00198-9</pub-id>
<pub-id pub-id-type="pmid">26361969</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Psarelli</surname><given-names>EE</given-names></name>, <name name-style="western"><surname>Berhane</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group><article-title>Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials</article-title>. <source>J Clin Oncol</source><year>2017</year>;<volume>35</volume>:<fpage>622</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2016.69.5197</pub-id>
<pub-id pub-id-type="pmid">28045619</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruix</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Meinhardt</surname><given-names>G</given-names></name>, <etal>et al</etal></person-group><article-title>Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies</article-title>. <source>J Hepatol</source><year>2017</year>;<volume>67</volume>:<fpage>999</fpage>–<lpage>1008</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhep.2017.06.026</pub-id>
<pub-id pub-id-type="pmid">28687477</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Llovet</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Peña</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Lathia</surname><given-names>CD</given-names></name>, <etal>et al</etal></person-group><article-title>Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma</article-title>. <source>Clin Cancer Res</source><year>2012</year>;<volume>18</volume>:<fpage>2290</fpage>–<lpage>300</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-2175</pub-id>
<pub-id pub-id-type="pmid">22374331</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simon</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Paik</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hayes</surname><given-names>DF</given-names></name></person-group><article-title>Use of archived specimens in evaluation of prognostic and predictive biomarkers</article-title>. <source>J Natl Cancer Inst</source><year>2009</year>;<volume>101</volume>:<fpage>1446</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/djp335</pub-id>
<pub-id pub-id-type="pmid">19815849</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lavoie</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Therrien</surname><given-names>M</given-names></name></person-group><article-title>Regulation of RAF protein kinases in ERK signalling</article-title>. <source>Nat Rev Mol Cell Biol</source><year>2015</year>;<volume>16</volume>:<fpage>281</fpage>–<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1038/nrm3979</pub-id>
<pub-id pub-id-type="pmid">25907612</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newell</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Toffanin</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Villanueva</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group><article-title>Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo</article-title>. <source>J Hepatol</source><year>2009</year>;<volume>51</volume>:<fpage>725</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhep.2009.03.028</pub-id>
<pub-id pub-id-type="pmid">19665249</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiang</surname><given-names>DY</given-names></name>, <name name-style="western"><surname>Villanueva</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hoshida</surname><given-names>Y</given-names></name>, <etal>et al</etal></person-group><article-title>Focal gains of VEGFA and molecular classification of hepatocellular carcinoma</article-title>. <source>Cancer Res</source><year>2008</year>;<volume>68</volume>:<fpage>6779</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-0742</pub-id>
<pub-id pub-id-type="pmid">18701503</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horwitz</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Stein</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Andreozzi</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group><article-title>Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment</article-title>. <source>Cancer Discov</source><year>2014</year>;<volume>4</volume>:<fpage>730</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0782</pub-id>
<pub-id pub-id-type="pmid">24687604</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Domingues</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Rino</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Demmers</surname><given-names>JA</given-names></name>, <etal>et al</etal></person-group><article-title>VEGFR2 translocates to the nucleus to regulate its own transcription</article-title>. <source>PLoS One</source><year>2011</year>;<volume>6</volume>:<elocation-id>e25668</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0025668</pub-id><pub-id pub-id-type="pmid">21980525</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoshida</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Nijman</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Kobayashi</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group><article-title>Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma</article-title>. <source>Cancer Res</source><year>2009</year>;<volume>69</volume>:<fpage>7385</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-1089</pub-id>
<pub-id pub-id-type="pmid">19723656</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaposi-Novak</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Gòmez-Quiroz</surname><given-names>L</given-names></name>, <etal>et al</etal></person-group><article-title>Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype</article-title>. <source>J Clin Invest</source><year>2006</year>;<volume>116</volume>:<fpage>1582</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1172/JCI27236</pub-id>
<pub-id pub-id-type="pmid">16710476</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coulouarn</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Factor</surname><given-names>VM</given-names></name>, <name name-style="western"><surname>Thorgeirsson</surname><given-names>SS</given-names></name></person-group><article-title>Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer</article-title>. <source>Hepatology</source><year>2008</year>;<volume>47</volume>:<fpage>2059</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1002/hep.22283</pub-id>
<pub-id pub-id-type="pmid">18506891</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tovar</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Alsinet</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Villanueva</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group><article-title>IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage</article-title>. <source>J Hepatol</source><year>2010</year>;<volume>52</volume>:<fpage>550</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhep.2010.01.015</pub-id>
<pub-id pub-id-type="pmid">20206398</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villanueva</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Alsinet</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Yanger</surname><given-names>K</given-names></name>, <etal>et al</etal></person-group><article-title>Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice</article-title>. <source>Gastroenterology</source><year>2012</year>;<volume>143</volume>:<fpage>1660</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2012.09.002</pub-id>
<pub-id pub-id-type="pmid">22974708</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villanueva</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Chiang</surname><given-names>DY</given-names></name>, <name name-style="western"><surname>Newell</surname><given-names>P</given-names></name>, <etal>et al</etal></person-group><article-title>Pivotal role of mTOR signaling in hepatocellular carcinoma</article-title>. <source>Gastroenterology</source><year>2008</year>;<volume>135</volume>:<fpage>1972</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2008.08.008</pub-id>
<pub-id pub-id-type="pmid">18929564</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woo</surname><given-names>HG</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>ES</given-names></name>, <name name-style="western"><surname>Cheon</surname><given-names>JH</given-names></name>, <etal>et al</etal></person-group><article-title>Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma</article-title>. <source>Clin Cancer Res</source><year>2008</year>;<volume>14</volume>:<fpage>2056</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-1473</pub-id>
<pub-id pub-id-type="pmid">18381945</pub-id></mixed-citation>
              </ref>
              <ref id="R29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mínguez</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Hoshida</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Villanueva</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group><article-title>Gene-expression signature of vascular invasion in hepatocellular carcinoma</article-title>. <source>J Hepatol</source><year>2011</year>;<volume>55</volume>:<fpage>1325</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhep.2011.02.034</pub-id>
<pub-id pub-id-type="pmid">21703203</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tovar</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Cornella</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Moeini</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group><article-title>Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma</article-title>. <source>Gut</source><year>2017</year>;<volume>66</volume>:<fpage>530</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1136/gutjnl-2015-309501</pub-id>
<pub-id pub-id-type="pmid">26658144</pub-id></mixed-citation>
              </ref>
              <ref id="R31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Villanueva</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hoshida</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Battiston</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group><article-title>Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma</article-title>. <source>Gastroenterology</source><year>2011</year>;<volume>140</volume>:<fpage>1501</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2011.02.006</pub-id>
<pub-id pub-id-type="pmid">21320499</pub-id></mixed-citation>
              </ref>
              <ref id="R32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyault</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Rickman</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>de Reyniès</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group><article-title>Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets</article-title>. <source>Hepatology</source><year>2007</year>;<volume>45</volume>:<fpage>42</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1002/hep.21467</pub-id>
<pub-id pub-id-type="pmid">17187432</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakagawa</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>WM</given-names></name>, <etal>et al</etal></person-group><article-title>Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition</article-title>. <source>Cancer Cell</source><year>2016</year>;<volume>30</volume>:<fpage>879</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.ccell.2016.11.004</pub-id>
<pub-id pub-id-type="pmid">27960085</pub-id></mixed-citation>
              </ref>
              <ref id="R34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoshida</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Villanueva</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kobayashi</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group><article-title>Gene expression in fixed tissues and outcome in hepatocellular carcinoma</article-title>. <source>N Engl J Med</source><year>2008</year>;<volume>359</volume>:<fpage>1995</fpage>–<lpage>2004</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa0804525</pub-id>
<pub-id pub-id-type="pmid">18923165</pub-id></mixed-citation>
              </ref>
              <ref id="R35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sprinzl</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Reisinger</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Puschnik</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group><article-title>Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells</article-title>. <source>Hepatology</source><year>2013</year>;<volume>57</volume>:<fpage>2358</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1002/hep.26328</pub-id>
<pub-id pub-id-type="pmid">23424039</pub-id></mixed-citation>
              </ref>
              <ref id="R36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>WC</given-names></name>, <etal>et al</etal></person-group><article-title>Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity</article-title>. <source>Int J Cancer</source><year>2014</year>;<volume>134</volume>:<fpage>319</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.28362</pub-id>
<pub-id pub-id-type="pmid">23818246</pub-id></mixed-citation>
              </ref>
              <ref id="R37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>YR</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>WB</given-names></name>, <name name-style="western"><surname>Lian</surname><given-names>ZX</given-names></name>, <etal>et al</etal></person-group><article-title>Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma</article-title>. <source>Oncotarget</source><year>2016</year>;<volume>7</volume>:<fpage>38292</fpage>–<lpage>305</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.9438</pub-id>
<pub-id pub-id-type="pmid">27203677</pub-id></mixed-citation>
              </ref>
              <ref id="R38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sia</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Jiao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Martinez-Quetglas</surname><given-names>I</given-names></name>, <etal>et al</etal></person-group><article-title>Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features</article-title>. <source>Gastroenterology</source><year>2017</year>;<volume>153</volume>:<fpage>812</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2017.06.007</pub-id>
<pub-id pub-id-type="pmid">28624577</pub-id></mixed-citation>
              </ref>
              <ref id="R39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charoentong</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Finotello</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Angelova</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group><article-title>Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade</article-title>. <source>Cell Rep</source><year>2017</year>;<volume>18</volume>:<fpage>248</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2016.12.019</pub-id>
<pub-id pub-id-type="pmid">28052254</pub-id></mixed-citation>
              </ref>
              <ref id="R40">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ayers</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lunceford</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Nebozhyn</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group><article-title>IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade</article-title>. <source>J Clin Invest</source><year>2017</year>;<volume>127</volume>:<fpage>2930</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1172/JCI91190</pub-id>
<pub-id pub-id-type="pmid">28650338</pub-id></mixed-citation>
              </ref>
              <ref id="R41">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quigley</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Pereyra</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Nilsson</surname><given-names>B</given-names></name>, <etal>et al</etal></person-group><article-title>Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF</article-title>. <source>Nat Med</source><year>2010</year>;<volume>16</volume>:<fpage>1147</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2232</pub-id>
<pub-id pub-id-type="pmid">20890291</pub-id></mixed-citation>
              </ref>
              <ref id="R42">
                <label>42</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Radaeva</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jaruga</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>F</given-names></name>, <etal>et al</etal></person-group><article-title>Interferon-alpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes</article-title>. <source>Gastroenterology</source><year>2002</year>;<volume>122</volume>:<fpage>1020</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1053/gast.2002.32388</pub-id>
<pub-id pub-id-type="pmid">11910354</pub-id></mixed-citation>
              </ref>
              <ref id="R43">
                <label>43</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilhelm</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Carter</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>L</given-names></name>, <etal>et al</etal></person-group><article-title>BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis</article-title>. <source>Cancer Res</source><year>2004</year>;<volume>64</volume>:<fpage>7099</fpage>–<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-1443</pub-id>
<pub-id pub-id-type="pmid">15466206</pub-id></mixed-citation>
              </ref>
              <ref id="R44">
                <label>44</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vogel</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Cobleigh</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Tripathy</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group><article-title>Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer</article-title>. <source>J Clin Oncol</source><year>2002</year>;<volume>20</volume>:<fpage>719</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2002.20.3.719</pub-id>
<pub-id pub-id-type="pmid">11821453</pub-id></mixed-citation>
              </ref>
              <ref id="R45">
                <label>45</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karapetis</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Khambata-Ford</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jonker</surname><given-names>DJ</given-names></name>, <etal>et al</etal></person-group><article-title>K-ras mutations and benefit from cetuximab in advanced colorectal cancer</article-title>. <source>N Engl J Med</source><year>2008</year>;<volume>359</volume>:<fpage>1757</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa0804385</pub-id>
<pub-id pub-id-type="pmid">18946061</pub-id></mixed-citation>
              </ref>
              <ref id="R46">
                <label>46</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amado</surname><given-names>RG</given-names></name>, <name name-style="western"><surname>Wolf</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Peeters</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group><article-title>Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer</article-title>. <source>J Clin Oncol</source><year>2008</year>;<volume>26</volume>:<fpage>1626</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2007.14.7116</pub-id>
<pub-id pub-id-type="pmid">18316791</pub-id></mixed-citation>
              </ref>
              <ref id="R47">
                <label>47</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Negri</surname><given-names>FV</given-names></name>, <name name-style="western"><surname>Dal Bello</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Porta</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group><article-title>Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment</article-title>. <source>Liver Int</source><year>2015</year>;<volume>35</volume>:<fpage>2001</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/liv.12778</pub-id>
<pub-id pub-id-type="pmid">25559745</pub-id></mixed-citation>
              </ref>
              <ref id="R48">
                <label>48</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Personeni</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Rimassa</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Pressiani</surname><given-names>T</given-names></name>, <etal>et al</etal></person-group><article-title>Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma</article-title>. <source>J Cancer Res Clin Oncol</source><year>2013</year>;<volume>139</volume>:<fpage>1179</fpage>–<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1007/s00432-013-1429-x</pub-id>
<pub-id pub-id-type="pmid">23568548</pub-id></mixed-citation>
              </ref>
              <ref id="R49">
                <label>49</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ji</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group><article-title>Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint</article-title>. <source>Oncotarget</source><year>2016</year>;<volume>7</volume>:<fpage>41274</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.8978</pub-id>
<pub-id pub-id-type="pmid">27129180</pub-id></mixed-citation>
              </ref>
              <ref id="R50">
                <label>50</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmitz</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Wohlschlaeger</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lang</surname><given-names>H</given-names></name>, <etal>et al</etal></person-group><article-title>Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection</article-title>. <source>J Hepatol</source><year>2008</year>;<volume>48</volume>:<fpage>83</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhep.2007.08.018</pub-id>
<pub-id pub-id-type="pmid">17998146</pub-id></mixed-citation>
              </ref>
              <ref id="R51">
                <label>51</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burkhart</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Ronnekleiv-Kelly</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Pawlik</surname><given-names>TM</given-names></name></person-group><article-title>Personalized therapy in hepatocellular carcinoma: Molecular markers of prognosis and therapeutic response</article-title>. <source>Surg Oncol</source><year>2017</year>;<volume>26</volume>:<fpage>138</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.suronc.2017.01.009</pub-id>
<pub-id pub-id-type="pmid">28577719</pub-id></mixed-citation>
              </ref>
              <ref id="R52">
                <label>52</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McShane</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Hayes</surname><given-names>DF</given-names></name></person-group><article-title>Publication of tumor marker research results: the necessity for complete and transparent reporting</article-title>. <source>J Clin Oncol</source><year>2012</year>;<volume>30</volume>:<fpage>4223</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2012.42.6858</pub-id>
<pub-id pub-id-type="pmid">23071235</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
